MannKind (MNKD)
(Delayed Data from NSDQ)
$6.00 USD
+0.17 (2.92%)
Updated Jul 16, 2024 03:56 PM ET
After-Market: $6.01 +0.01 (0.17%) 7:20 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MNKD 6.00 +0.17(2.92%)
Will MNKD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MNKD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNKD
All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy
Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
MNKD: What are Zacks experts saying now?
Zacks Private Portfolio Services
MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
Other News for MNKD
Buy Recommendation: MannKind’s Afrezza Shows Promising Efficacy and Market Growth Potential
MannKind announces 17-week results from INHALE-3 study
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
MannKind initiated with bullish view at Rodman & Renshaw
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions